Merck KGaA is doubling down on AI through a new collaboration agreement with tech firm Iktos, using its generative modelling technology to speed up the discovery and design of promising new compounds.

Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery. Do you know someone who can make tough decisions that continue to face manufacturers?

Merck & Co. is rounding out its March deal flurry with an antibody discovery pact that could be worth as much as $838 million. The New Jersey pharma is tapping Infinimmune to hunt for antibodies for ...

Merck & Co. has lifted the lid on the third successful phase 3 trial of its PCSK9 inhibitor, showing the edge the cardiovascular disease prospect has over other oral non-statin therapies. Last year, ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 trial. The ...

March 31 (Reuters) - Biotech firm Infinimmune said on Tuesday it has entered into a deal with drugmaker Merck (MRK.N), opens new tab that ‌could be worth up to about $838 million in milestone payments ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

Merck & Co., Inc. is currently listed on NYSE under MRK. One share of MRK stock can currently be purchased for approximately $114.62. Is Merck & Co., Inc. (MRK) overvalued or undervalued? Merck & Co., ...

Optical sensors are a broad class of device for detecting light intensity. This can be just a simple component for notifying when ambient light levels rise above or fall below a prescribed level, or a ...